Please use this identifier to cite or link to this item:
Title: Pharmaceutical acetylation can modulate the amyloidogenicity of human serum albumin
Authors: Bharathi, Vidhya
Manglunia, Ruchi Rajkumar
Sharma, Neetu
Nirwal, Sadhana
Patel, Basant K
Keywords: Acetylation;Human serum albumin;Sarkosyl;Thioflavin-T
Issue Date: Aug-2021
Publisher: NIScPR-CSIR, India
Abstract: Human serum albumin (HSA) is an abundant carrier protein present in the blood plasma manifesting affinity for drugs and ligands. The bindings of several drugs can cause changes in the structural conformation of HSA that may affect its function. HSA is also known to in vitro form amyloid-like aggregates with fibrillar morphology as observed under TEM. Earlier, we showed that the HSA amyloid-like aggregates display self-seeding potential and detergent stability and the dimers of HSA, which are preferable for clinical applications due to their longer circulatory life, can also form amyloid-like aggregates. As aspirin, a commonly prescribed drug, was previously documented to acetylate HSA at one of its lysine residues, here, we examined if acetylation has any effect on the in vitro amyloid-like aggregation of HSA. We show that HSA acetylated in vitro using acetylsalicylic acid manifests relatively reduced levels of amyloid-specific properties such as turbidity, Thioflavin-T-positive aggregation, -sheet content and stability against an ionic detergent. Also, TEM imaging shows that the acetylated HSA forms relatively less aggregates and with smaller sizes whereas, the aggregates of HSA are more abundant and larger in sizes with fibrillar morphology which further supports that acetylation can attenuate the amyloid-like aggregation of HSA.
Page(s): 344-351
ISSN: 0975-0959 (Online); 0301-1208 (Print)
Appears in Collections:IJBB Vol.58(4) [August 2021]

Files in This Item:
File Description SizeFormat 
IJBB 58(4) 344-351.pdf1.66 MBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.